Glucotrack to participate in forgetdiabetes, a prominent european research initiative to develop a bionic pancreas

Rutherford, n.j., april 16, 2025 (globe newswire) -- glucotrack, inc. (nasdaq: gctk) (“glucotrack” or the “company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the forgetdiabetes bionic pancreas initiative that will develop a long-term, automated insulin delivery system that will enable optimal glucose control without patient intervention.
GCTK Ratings Summary
GCTK Quant Ranking